Introduction
Interleukin-2 (IL-2) is a major autocrine growth factor for T lymphocytes . It is the principal cytokine responsible for the progression of T lymphocytes from the G1 to S phase of the cell cycle (Stern and Smith, 1986) . IL-2 also stimulates growth of natural killer (NK) cells and enhances their cytolytic functions (reviewed in Whiteside and Herberman, 1995) . It acts as a growth factor for human B cells and as a stimulus for antibody synthesis (Ralph et al., 1984; Nakanishi et al., 1992) . IL-2 produced by lymphoid cells is a 14 ± 17 kD glycoprotein, depending on a variable extent of its glycosylation, and it is encoded by a single gene on chromosome 4 in humans (Seigel et al., 1984) . The action of IL-2 on hemopoietic cells is mediated by its binding to the IL-2 receptor complex, which contains at least three distinct chains: a, b and g. The IL-2Ra-chain (p55) alone is the low anity receptor (K d =10 78 M), while the IL-2Rb-chain (p70/75) in association with the IL-2Rg-chain (p64) together binds IL-2 with intermediate anity
79 M). The non-covalent association of the IL-2Ra-, IL-2Rb-and IL-2Rg-chains results in expression of a high anity receptor, with K d =10 711 M (Taniguchi and Minami, 1993) . IL-2 mediated signals for stimulation and proliferation of lymphocytes are transmitted through the IL-2Rb-and IL-2Rg-chains, because the a-chain lacks the cytoplasmic domain necessary for signal transduction. The IL-2Rg-chain has been shown to be responsible for internalization of the IL-2/IL-2R complex in addition to its signaltransducing function (Takeshita et al., 1992) .
We have reported previously that human carcinomas spontaneously express abundant IL-2Rb, IL-2Rg and very little IL-2Ra on the cell surface, contain mRNA for these receptor chains, and are inhibited in growth by high molar concentrations of exogenously-delivered IL-2 in vitro and in vivo, in a xenograft model of tumor growth in nude mice (Rabinowich et al., 1992; Weidmann et al., 1992; Yasumura et al., 1994; Lin et al., 1995) . Others have reported expression of IL-2Ra-and b-chains on a variety of normal and malignant cells, including human embryonic ®broblasts , melanoma cells (Rimoldi et al., 1993) , pituitary cells (Artz et al., 1992) , or intestinal epithelial cells (Ciacci et al., 1993) . The presence of IL-2Rb on human carcinomas appeared to be necessary for growth of tumor cell lines, because anti-sense cDNA to IL-2Rb was found to inhibit growth of tumor cells cultured in the absence of exogenous IL-2 (Lin et al., 1995) .
More recently, IL-2 protein and mRNA were also found to be expressed in several human carcinomas in vitro and in vivo by us and others (Lin et al., 1995; McMillan et al., 1995) . In addition to intracellular IL-2, cell surface-associated IL-2, presumably bound to IL-2R on tumor cells, was detected by immunostaining and ow cytometry on variable proportions of tumor cells in culture grown in the absence of exogenous IL-2 (Lin et al., 1995) . Thus, endogenous IL-2 appears to be able to bind to IL-2Rb expressed on the cell surface of carcinoma cells. Interference with expression of endogenous IL-2 using IL-2-speci®c antisense oligonucleotides was found to result in the inhibition of growth and an increased rate of apoptosis in tumor cells. We have reported that in monolayers of tumor cells and in human tumors in situ, IL-2 is especially strongly expressed in dividing cells . To test the possibility that endogenous IL-2 is involved in the regulation of tumor cell division, we examined the expression of IL-2 and its receptors in various phases of the cell cycle in tumor cell lines. By¯ow cytometry and immunostaining, expression of these proteins was found to be induced in the S phase, and signi®cantly upregulated in the G2/M phase of the cell cycle. Changes in expression of the cyclin-dependent kinase inhibitors p27 and p21 were followed in the same tumor cells and found to be cell cycle dependent. More importantly, direct inhibition of IL-2 production by using IL-2-speci®c antisense oligonucleotide resulted in an increase in the levels of p27 and p21 expression. The results suggested that in tumor cells, endogenous IL-2 might mediate the cell cycle progression through regulating levels of expression of CDK inhibitors.
Results

Immunostaining of tumor cells
Immunohistochemistry was used to observe the presence and distribution of IL-2 or IL-2R in cellular compartments of human carcinoma cells and Jurkat cells or ConA-activated normal T cells used as controls. Almost all tumor cells grown in chamber slides were found to constitutively express IL-2. These cells showed a characteristic staining pattern, with immunoreactive IL-2 strongly localized to a circumscribed area in the cytoplasm (Figure 1a,b) . PHA-stimulated Jurkat T cells or ConA-activated normal T lymphocytes also showed the same staining pattern. In tumor cell monolayers, the strongest staining for IL-2 was seen in cells undergoing mitosis, and nearly all mitotic cells were positive ( Figure  1d ). Jurkat cells or normal activated T cells and normal keratinocytes did not stain more intensely in mitosis than in G0/G1 (not shown).
Immunostaining with an Ab to the IL-2R b-chain was strongly positive in all tumor cells. The strongest staining was observed in the perinuclear area of the cytoplasm. Mitotic cells were especially strongly stained (Figure 1f ). Tumor cells did not express the IL-2R a-chain (Figure 1e ), while among ConAstimulated T cells used as a positive control, 40 ± 50% of cells showed strong expression of IL-2Ra (not shown).
With an Ab against the IL-2R g-chain, positive staining was observed in the cytoplasm of almost all tumor cells, again with more intense staining of mitotic cells (Figure 1g ).
Flow cytometry of synchronized tumor cells
Flow cytometry analyses of various tumor cell suspensions con®rmed the results obtained with The IL-2/IL-2R pathway in human carcinomas TE Reichert et al immunohistochemistry. Initially, when HR tumor cells were synchronized in the S or M phase of the cell cycle, as described in Materials and methods, and examined for expression of intracytoplasmic IL-2, a considerable upregulation of IL-2 expression was seen in the M vs S phase (Figure 2) . A more detailed study performed with PCI-1 cells showed up-regulation of cytoplasmic IL-2, IL-2Rb-and g-chain in synchronized G2/M phase PCI-1 cells as compared to G0/G1 cells ( Figure  3) . The up-regulation of the IL-2 protein level was already detectable in cells which were in the S phase of the cell cycle. The IL-2 protein, which was associated with the cell surface in non-permeabilized tumor cells (Figure 3b ), was weakly expressed in all three tumor cell lines studied. No dierence in expression of surface IL-2 between the G0/G1 and G2/M phase cells was noted (Figure 3b ). There was no or only weak expression of surface IL-2R-g in these cells ( Figure  3b ). The cell surface-associated IL-2Rb was clearly positive in all tumor cell lines studied, with a slight upregulation in the G2/M phase ( Figure 3b) .
In primary cultures of keratinocytes and in stimulated T cells, changes in levels of IL-2, IL-2Rb and g protein expression were not detected in the dierent phases of the cell cycle (data not shown).
In parallel to immunohistology,¯ow cytometry studies of tumor cells showed no or very little IL2Ra expression on the cell surface and in the cytoplasm, in contrast to stimulated T cells which expressed considerable levels of surface as well as cytoplasmic IL-2Ra. There was no modulation of IL2Ra in the course of the cell cycle in tumor or T cells (data not shown).
Expression of IL-2 mRNA in tumor cells during the cell cycle
To determine the level of mRNA for IL-2 in nondividing vs mitotic cells, we performed quantitative competitive RT ± PCR. In all tumor cell lines, we observed a 5 ± 10-fold upregulation of the IL-2 mRNA level in synchronized G2/M phase cells in comparison to G0/G1-cells ( Figure 4 , the ®rst three panels and Table 1 ). An increase in the copy number of IL-2 Figure 2 Expression of endogenous IL-2 in HR cells synchronized in the M phase or S phase of the cell cycle. HR tumor cells were synchronized as described in Material and methods, permeabilized and stained for intracytoplasmic IL-2, and examined by¯ow cytometry. Note up-regulation of endogenous IL-2 in the M phase of the cell cycle Figure 3 Flow cytometry histograms demonstrating the presence of (a) intracellular and (b) cell surface-associated IL-2, IL-2Rb and IL-2Rg in PCI-1 cells in dierent phases of the cell cycle. Flow cytometry was performed as described in Materials and methods, and the data are presented as log¯uorescence intensity. Isotype control Abs were used to control for nonspeci®c staining
The IL-2/IL-2R pathway in human carcinoma TE Reichert et al mRNA was already visible in the S phase of the synchronized tumor cells (Table 1 ). The IL-2 mRNA level in tumor cells was higher than in normal keratinocytes but markedly lower than that in PHAstimulated Jurkat cells or Con A-stimulated T cells (Table 1 and Figure 4 , the last panel).
Expression of CDK inhibitors p27 and p21 in synchronized carcinoma cells
In view of the observation that the intracytoplasmic expression of IL-2 was low in G0/G1, increased in S and further increased in G2/M phase of synchronized tumor cells (Figure 3a) , we hypothesized that the increase in IL-2 might play a role in the G1 to S transition of the cell cycle. If so, IL-2 might suppress expression of some G1 phase-speci®c inhibitors. To test this hypothesis, we measured the level of the CDK inhibitor p27 in synchronized PCI-1 tumor cells. Using staining and¯ow cytometry, we detected high levels of p27 in the G0/G1 phase. The level of the p27 was decreased in the S phase ( Figure 5c ). Western blot assays con®rmed a dramatic decrease in the p27 protein levels during the G1 to S transition ( Figure  5b , lanes 4 vs 3). Interestingly, both immunostaining and immunoblotting assays demonstrated that the level of p27 expression was high in the G2/M cells ( Figure  5b , lanes 5, 5c). These results suggest that instead of completely suppressing p27 expression, the IL-2-mediated signal pathway only lowers the threshold level of p27, which may be important for the M to G1 transition.
To further evaluate the possibility that cell cycle associated changes in p27 expression coincide with changes of endogenous IL-2 expression in tumor cells, we synchronized HR cells and simultaneously measured relative levels of IL-2 and p27 expression by¯ow cytometry. As shown in Figure 6 , the level of endogenous IL-2 is relatively low and that of p27 high in G0/G1. The IL-2 level begins to rise in the S phase, at the time when the lowest p27 expression is observed. In the M phase, intracellular expression level of IL-2 is the highest, while that of p27 returns to a high pre-mitotic level ( Figure 6 ). To more convincingly demonstrate these patterns of changes, we calculated DMFI for IL-2 and p27 in various phases of the cell cycle in¯ow cytometry experiments performed with synchronized PCI-13, PCI-1 and HR cell lines. As shown in Table 3 , DMFI for IL-2 increased in the S phase, while DMFI for p27 decreased. Taken together, these data indicate that cell cycle associated changes occur in both proteins and suggest that in the S phase, decreased p27 expression is associated with higher expression of IL-2, as reported for lymphoid cells (Nourse et al., 1994) . Figure 4 Quantitative competitive reverse transcription-polymerase chain reaction (RT ± PCR) for IL-2 transcripts in total RNA obtained from PCI-1 tumor cells synchronized in the G0/G1, S, or G2/M phase of the cell cycle and from ConA-stimulated normal T lymphocytes. Aliquots of the total RNA (300 ng) isolated from the cells were analysed in a series of reactions with increasing concentrations of the internal control (cRNA of pQA-1), each reaction containing the known number of control RNA copies. PCR was performed under conditions described in Materials and methods. PCR products were separated by polyacrylamide gel electrophoresis. The log ratio of the c.p.m. [ 32 P] of internal control to c.p.m. of cellular RNA was plotted, and the copy number/mg total cellular RNA was calculated as previously described . The IL-2 mRNA copy number for PCI-1 cells in G0/G1=135/mg, in S=170/mg and in G2/M=697/mg total RNA. Activated T cells showed a copy number of 7.4610 4 mg total RNA The IL-2 mRNA copy number/mg total RNA was determined by using quantitative competitive RT ± PCR as described . The data are from a represenative experiment of three performed. b Total cellular RNA from synchronized tumor cells in dierent phases of the cell cycle was extracted as described in Materials and methods.
c T lymphocyte and Jurkat cells were activated by incubation with Con A (10 mg/ml) or PHA (10 mg/ml) in RPMI medium containing 10% (v/v) FCS, 2 mM glutamine and antibiotics for 36 h
The IL-2/IL-2R pathway in human carcinomas TE Reichert et al In addition, PCI-13 cells were synchronized by using aphidicolin at the G1/S boundary and then released by adding fresh medium to the cells. Flow cytometry performed on an aliquot of these cells indicated that at 6 h after release, the majority of tumor cells were in the S phase of the cell cycle (Figure 7a ). At that time, expression of intracellular IL-2 was increased relative to that at the G0/G1 phase. Importantly, by Western blots, PCI-13 cells contained decreased levels of p27 at 6 h after their release, as shown in Figure 7b . These data again support the inverse relationship between p27 and IL-2 during the S phase. In contrast to p27, the p21 levels were increased during the G1 to S transition (Figure 7b ). Only at 24 h after release, the p21 levels were decreased, whereas the IL-2 levels remained high (Figure 7b ).
Expression of p27 and p21 CDK inhibitors in tumor cells blocked by the IL-2-specific AS oligonucleotide
To provide more direct evidence that changes in endogenous IL-2 expression regulate the level of p27 and perhaps p21 expression, an ASO was used to inhibit the synthesis of IL-2 mRNA as well as protein and tumor cell growth under conditions described in Materials and methods. Non-synchronized cultures of tumor cells were incubated with the ASO or SO phosphorothioates for various periods of time. Western blots performed at 24 h, when IL-2 mRNA and cell growth were only partially inhibited, showed no increase in expression of p27 in ASO-treated cells (Figure 8 ). On the other hand, at 48 h, when ASO optimally inhibited IL-2 mRNA and cell growth (see Table 2 and Figure 8 ), the level of p27 was markedly increased, compared to that seen in cells treated with IL-2-speci®c SO. In contrast, the p21 level was found to be increased at both 24 h and 48 h in ASO-treated tumor cells (Figure 8 ). Thus, p21 expression appeared to be aected earlier and more strongly than p27 expression by the treatment of tumor cells with IL-2-speci®c ASO. These results suggested that the presence of endogenous IL-2 was necessary for the downregulation of p27 and p21 CDK inhibitors and the cell cycle progression in tumor cells.
Treatment of tumor cells with p27-or p21-specific antisense oligonucleotides
When non-synchronized tumor cells were incubated in the presence of the ASO speci®c for p27 or p21 for 24 h, expression of both CDK inhibitors was substantially decreased, as shown in Figure 9a ,b. However, expression of endogenous IL-2 at the mRNA ( Figure  9c ) or protein level (not shown) was not altered in the Figure 5 Cell cycle patterns of p27 protein in PCI-1 cells. In (a), exponentially grown PCI-1 tumor cells were synchronized in G0/ G1, S or G2/M phases of the cell cycle for the Western blot experiment by using serum starvation, aphidicolin, or mitotic shake-o', respectively, as described in Materials and methods. In (b), PCI-1 tumor cells growing exponentially (lane 2) or synchronized in G0/G1 (lane 3), S (lane 4) or G2/M (lane 5) were lysed and the prepared lysates were then analysed in a Western blot assay using speci®c antibodies to human p27. Lane 1, a lysate prepared from human breast cancer MCF-7 cells that had been treated with anticancer agent etoposide (VP-16) for 20 h and which contains p27 (positive control). In (c), intracytoplasmic expression of p27 in PCI-1 cells during the cell cycle, as determined by¯ow cytometry. PCI-1 cells synchronized in various stages of the cell cycle were permeabilized, stained with antibodies to p27 and examined by¯ow cytometry
The IL-2/IL-2R pathway in human carcinoma TE Reichert et al same cells. This series of experiments suggested that IL-2 might act up-stream of the CDK inhibitors and, therefore, changes in p27 or p21 expression had no impact on IL-2 expression in carcinoma cells.
Discussion
The IL-2R appears to be expressed not only on hematopoietic cells but also on a wide variety of non-hematopoietic cells, including normal and malignant cells of the epithelial origin (Saneto et al., 1986; Weidmann et al., 1992; Plaisance et al., 1992 Plaisance et al., , 1993 Artz et al., 1992; Alileche et al., 1993; Ciacci et al., 1993; Yasumura et al., 1994; Lin et al., 1995; McMillan et al., 1995) . Functions of the IL-2R chains in nonhematopoietic cells are not fully understood. Binding of exogenous recombinant IL-2 to the IL-2R complex on these cells has been variously reported to enhance, decrease or not aect cell proliferation (Saneto et al., 1986; Weidmann et al., 1992; Yasumura et al., 1994; McMillan et al., 1995) . In addition, exogenous IL-2 was shown to induce changes in expression of surface markers (ICAM-1, HLA class I, HLA-DR and CD44) known to be associated with tumor progression Plaisance et al., 1993) . IL-2 is synthesized and secreted primarily by activated T lymphocytes Hatakeyama et al., 1990) . For a long time, IL-2 was thought to act only on cells of lympho-hematopoietic origin (Waldmann, 1991). More recently, it was shown that non-hematopoietic cells are also capable of IL-2 production and secretion (Alileche et al., , 1994 Lin et al., 1995; McMillan et al., 1995) . Alileche and coworkers reported production and secretion of biologically active IL-2 in the human melanoma cell line M14 and in myo®broblasts from post-radiation ®brosis in breast cancer (Alileche et al., 1994) . McMillan and colleagues showed the presence of immunoreactive IL-2 in situ in a variety of human tumors as well as in tumor cell lines derived from these tumors (McMillan et al., 1995) . We have recently reported that human carcinoma cell lines not only express IL-2R but contain mRNA for IL-2 and express IL-2 protein in the cytoplasm and on the cell surface (Lin et al., 1995) . In non-dividing tumor cells, immunoreactive IL-2 was localized in the cytoplasm, but had a juxtanuclear distribution. The same pattern, probably re¯ecting IL-2 accumulation in the Golgi complex, was observed in in vitro-activated IL-2-producing normal T cells or Jurkat cells. We were able to con®rm, using a Golgi-speci®c mAb that IL-2 was indeed localized within the Golgi zone . These results are in agreement with the fact that IL-2, like most of the cytokines, contains hydrophobic amino acid-binding sequences, which leads to its accumulation in and secretion through the Golgi (Hatakeyama and Taniguchi, 1990) .
Our observations indicate that the level of IL-2 mRNA and IL-2/IL-2R protein expression in tumor cells becomes altered during the cell cycle: IL-2, IL2Rb and g are particularly abundant in the G2/M Figure 6 Expression of endogenous IL-2 and p27 in HR tumor cells synchronized in G0/G1, S and G2/M phases of the cell cycle (upper panels). The synchronized cells were permeabilized and divided into two aliqouts, one to be stained for IL-2, the other for p27 expression. The cells were examined by¯ow cytometry, and the data are presented as log¯uorescence intensity. A representative experiment of ®ve performed with HR and PCI-1 cells
The IL-2/IL-2R pathway in human carcinomas TE Reichert et al phase. In dividing tumor cells, IL-2 and IL-2R are evenly distributed throughout the cell, probably re¯ecting fragmentation of cellular organelles into a set of smaller vesicles, which can be evenly distributed when the cell divides (Alberts et al., 1994) . In activated T lymphocytes, where IL-2 is known to be responsible for the progression from G1 to S phase Stern and Smith, 1986) , and in normal human tissue cells (keratinocytes), we did not detect mitosisassociated up-regulation of IL-2 or IL-2R. The high level of IL-2 and IL-2R expression observed during mitosis in human carcinomas leads to the hypothesis that IL-2 may be involved in the process of cellular division in these cells, analogous to its regulation of CDK activity in G1/S in T lymphocytes (Nourse et al., 1994) . To test this hypothesis, expression of CDK inhibitors was compared in carcinoma cells synchronized in G0/G1, S and G2/M phases of the cell cycle, using three dierent methods (Figures 5 and 6 ) and tumor cells synchronized at G1/S and released from the block (Figure 7 ). We were able to document that a decrease of p27 CDK inhibitor expression coincided with an increase of IL-2 in carcinoma cells during the G1 to S transition (Figures 5 ± 7) . Thus, by analogy to T cells (Nourse et al., 1994) , IL-2 appears to be able to transiently suppress expression of p27, thus allowing carcinoma cells to pass the G1 restriction point (Pardee, 1989) . Using synchronized tumor cells, we observed accumulation of intracellular IL-2 in the G2/ M phase, indicating that IL-2 also plays an important role in the process of cell division. A signi®cant amount of p27 detected in the G2/M phase on Western blots (Figures 5 and 6 ) is unlikely to be due to the contaminating G1 cells, since the G1 cells only represent 55% of total cell population synchronized in the G2/M phase (see Figures 3 and 6) . One possible interpretation of this result is that p27 expression is induced in the M phase, but this induction is limited under a critical threshold by the high level of IL-2. During the M to G1 transition, IL-2 is down-regulated by an unknown mechanism(s), allowing a further increase in the level of p27 protein. In contrast to p27, levels of p21 remained relatively constant during the S and M phases of the cell cycle.
To further elucidate the relationship between endogenous IL-2 and p27 or p21 levels, tumor cells were treated with the IL-2 speci®c ASO and SO phosphorothioates to block IL-2 expression and interfere with cell Figure 7 Expression of IL-2, p27 and p21 in PCI-13 cells synchronized at the G1/S boundary by the treatment with aphidicolin (5 mg/ml for 24 h). After removal of aphidicolin, the cells were incubated in fresh growth medium for up to 24 h. Flow cytometry (a) was performed to determine the proportion of cells in the G0/G1, S and G2/M phases of the cell cycle. Expression of IL-2 was measured by¯ow cytometry (in a). Western blots were performed using the cell lysates and Abs speci®c for p27, and p21, (in b)
The IL-2/IL-2R pathway in human carcinoma TE Reichert et al growth (Table 2) , under conditions described earlier (Reichert et al., 1999) . While this strategy indicated that inhibition of endogenous IL-2 resulted in the upregulation of both p27 and p21 CDK inhibitor levels (Figure 8 ), it also suggested the existence of complex regulatory mechanisms involving this endogenous cytokine IL-2. Also, expression of p21 was found to be increased earlier than that of p27, and this occurred at the time of a partial growth arrest in tumor cells treated with IL-2-speci®c ASO. Thus, p21 CDK inhibitor was also sensitive to modulation mediated by endogenous IL-2 in tumor cells. However, in reciprocal type experiments, when tumor cells were treated with ASO speci®c for p27 or p21 (Figure 9 ), no changes in levels of IL-2 protein or mRNA for IL2 were observed. These results suggest that endogenous IL-2, acting up-stream, mod- The IL-2/IL-2R pathway in human carcinomas TE Reichert et al ulates expression of both CDK inhibitors, while its own expression is regulated independently of p21 or p27. It is interesting to note that not only IL-2 but also other cytokines, notably IL-4, are known to regulate cellular proliferation via the p27 CDK inhibitor (Liu et al., 1997) . TGF-b was also reported to increase cellular p27 or p21 levels (Miyazaki et al., 1998) . However, the carcinoma lines we studied do not express this cytokine, and it is unlikely that it contributes to the observed changes in the CDK inhibitor levels. IL-15, which we found to be abundantly expressed in our cell lines (data not shown) and which shares IL-2Rbg with IL-2, could be involved in the regulation of tumor cell growth. However, our earlier data showed that exogenous IL-15 had no eect on tumor cell proliferation (Suminami et al., 1998) . Furthermore, in tumor cells incubated in the presence of exogenous IL-15, levels of p21 or p27 CDK inhibitors were found to be unchanged relative to those in control cells, as evaluated in Western blots (unpublished data).
In contrast to the observed accumulation of IL-2/IL-2R in the cytoplasm of tumor cells in mitosis, the level of surface-bound IL-2 and IL-2Rb and g does not change much during the progression of the cell cycle (Figure 3) . In dividing tumor cells, more IL-2 and IL-2R are produced and expressed, but also more are internalized/endocytosed, as the process of IL-2R expression, IL-2 production, IL-2 binding and internalization of the IL-2/IL-2R complex is both rapid and dynamic (Duprez et al., 1988; Hemar et al., 1994) . It is also important to note that the levels of IL-2 mRNA and protein produced by tumor cells are low relative to those found in normal activated T lymphocytes or Jurkat cells. Nevertheless, the presence of endogenous IL-2 in carcinomas, which also express IL-2R, and its involvement in the regulation of the cell cycle suggest that this cytokine may be a growth factor not only for hematopoietic cells but also for tumor cells. In view of our results, it could be constructed that therapeutic delivery of IL-2 to patients with cancer might promote rather than inhibit tumor growth. However, exogenous IL-2 used at therapeutic doses was found to inhibit carcinoma growth in vitro and in vivo in nude mice (Weidmann et al., 1992; Rabinowich et al., 1992) . The opposite biologic eects of endogenous vs exogenous IL-2 described by us earlier (Reichert et al., 1999) emphasize the complexity of interactions between autocrine and exocrine IL-2 pathways.
Materials and methods
Cell lines and cells
Human SCCHN cell lines (PCI-1 and PCI-13) and HR (gastric carcinoma) cell line have been established in our laboratory as previously described (Heo et al., 1989; Shimizu et al., 1991) and maintained in Dulbecco's modi®ed-minimal essential medium (DMEM) containing 10% (v/v) heatinactivated (568C, 30 min) FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (all from Life Technologies, Inc., Grand Island, NY, USA). The cells were passaged by trypsinization (0.25% trypsin solution, Life Technologies, Grand Island, NY, USA) and were routinely tested for mycoplasma (GEN-PROBE, San Diego, CA, USA).
Primary cultures of human keratinocytes were kindly provided by Dr P Hebda, Department of Dermatology, UPMC. The lines were established from fresh surgical biopsies of normal human skin. Skin biopsies were placed in MCDB 153 medium (GIBCO), cut into 1 ± 2 mm 3 pieces, and explant cultures were established in serum-free MCDB 153 medium supplemented with bovine pituitary extract (GIBCO) in T25 plastic¯asks. After 7 days of culture, cells outgrowing from the explants were trypsinized, washed and seeded in wells of 24-well plastic plates in the same medium. These cells were passaged only once before they were used for experiments described below.
To prepare single cell suspensions from cellular monolayers for phenotypic or functional studies, tumor cell cultures were incubated either in the presence of cell dissociation solution (Sigma, St. Louis, MO, USA) or trypsinized as previously described (Weidman et al., 1992) . Following dissociation of monolayers, tumor cells were washed in tissue culture medium, counted and checked for viability in a Trypan blue dye and immediately used for experiments.
T cells were puri®ed from peripheral blood mononuclear cells by Ficoll-Hypaque gradient centrifugation from leukapheresed products obtained from platelet donors (Central Blood Bank of Pittsburgh) or from heparinized blood obtained from volunteers. To select for PBL, monocytes were removed on nylon wool columns (Lai et al., 1996) . T cells were isolated from PBL by negative selection, using immunomagnetic beads as previously described (Lai et al., 1996) . Two-color¯ow cytometry was used to con®rm the purity of negatively-selected T cell populations. For induction of expression of IL-2 and IL-2R, T cells were activated by incubation with 10 mg/ml Concanavalin A (Con A; Calbiochem Corp., La Jolla, CA, USA) or 10 mg/ml phytohemagglutinin (PHA; Sigma) in RPMI medium containing 10% (v/ v) heat-inactivated (568C, 30 min) FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (all from Life Technologies, Inc.) for 36 h.
Human Jurkat T cells, known to be producers of IL-2 after PHA stimulation and serving as a positive control in our studies, were maintained in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated FCS, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin (all from Life Technologies).
Antibodies to human IL-2 and IL-2R chains
Unlabeled polyclonal and monoclonal antibodies (mAbs) to IL-2 were purchased from Becton Dickinson (Mountain View, CA, USA) or R&D Systems (Minneapolis, MN, USA). Labeled mAbs to IL-2 were obtained from PharMingen (San Diego, CA, USA) or Biosource International (Camarillo, CA, USA). MAbs to the a-chain (CD25) of IL-2R were purchased from DAKO Corporation (Carpinteria, CA, USA) (unlabeled) or from Becton Dickinson (FITC-conjugated). The mAb TU27 (Takeshita et al., 1989) to the b-chain of IL-2R was kindly provided by Dr Kazuo Sugamura through Ajinomoto Co., Inc. (Kawasaki, Japan). The FITC-conjugated mAb to the b-chain (anti CD122) of IL-2R was bought from Endogen (Boston, MA, USA). The polyclonal chicken Ab to the IL-2R-g-chain was purchased from Promega (Madison, WI, USA). Labeled or unlabeled isotype control antibodies (IgG, IgM, IgG 2a or chicken IgG) were purchased from Becton Dickinson, DAKO Corporation, PharMingen or Biosource International.
Immunostaining for IL-2 and IL-2R
Tumor cell monolayers were grown to 70 ± 80% con¯uence on Labtek chamber slides (CMS, Houston, TX, USA). The slides were rinsed in cold PBS (263 min). The cells were pre®xed for 5 min in 2% paraformaldehyde (PFA), permeabilized and ®xed with 0.1% Triton X/PFA 2% for 10 min. TThe IL-2/IL-2R pathway in human carcinoma TE Reichert et al cell suspensions were washed in PBS, cytocentrifuged onto glass slides using a Shandon centrifuge (Sewickley, PA, USA), and ®xed/permeabilized, as described above. Indirect immunoperoxidase (IP) method (Chen et al., 1987) was used for staining with anti-IL-2 (30 mg/ml), TU27 and anti-CD 25 (10 mg/ml) or anti-human common g-chain (20 mg/ml) Abs. Prior to staining, polyclonal anti-IL-2 Ab (300 ml) was preincubated with excess rIL-2 (1.5610 6 Cetus U/ml; Chiron Corp., Emeryville, CA, USA) to verify its speci®city: this preincubation completely eliminated cytokine-speci®c staining. Isotype control Abs (IgG mouse, IgG chicken or IgG rabbit, as appropriate) were used in all experiments. Slides were examined in an Olympus BH-2 light microscope to determine expression of IL-2 and IL-2R proteins.
Flow cytometry
Expression of IL-2 and the dierent IL-2R chains on various tumor cell lines was determined by¯ow cytometry, using PEor FITC-conjugated anti-IL-2, FITC-conjugated anti-CD25, FITC-conjugated anti-CD122, and unlabeled TU27 or anticommon g-chain Abs. For surface staining, tumor cell suspensions were adjusted to the concentration of 1610 6 cells/ml in 0.1% (w/v) sodium azide in phosphate buered saline (PBS) and incubated with predetermined dilutions of appropriate Abs for 30 min at 48C. All Abs were pre-titered on normal non-activated or IL-2-activated PBMC to select optimal dilutions. Following staining, cells were washed twice with 0.1% sodium azide PBS, ®xed with 1% (w/v) PFA-PBS, and analysed in a¯ow cytometer. To detect intracellular protein expression, tumor cells were ®rst pre-®xed with 2% (w/v) PFA in PBS for 20 min at 48C, washed twice, permeabilized with 0.1% saponin (Sander et al., 1991) and stained with appropriate Abs. For indirect staining, cells were incubated ®rst with the primary Ab, washed three times, and then incubated with the FITC-conjugated second Ab (goat anti-mouse or goat anti-chicken). The appropriate isotype Igs or PBS alone were used as controls in all experiments.
For the cell cycle analysis, tumor cell suspensions were adjusted to 1610 6 cells/ml, ®xed overnight in 70% (v/v) ethanol at 48C, and incubated for at least 30 min with propidium iodide (PI, 50 mg/ml) and RNase A (100 U/ml) at room temperature. All analyses were performed in a FACScan¯ow cytometer (Becton Dickinson).
Synchronization of tumor cells
Serum starvation was used to synchronize tumor cells in the G0/G1-phase of the cell cycle. Tumor cell monolayers were cultured in DMEM medium with 10% FCS until 80% con¯uent. The cells were next incubated in medium without FCS for 48 h to arrest them in G0/G1. Those cells which had passed the restriction point (Pardee, 1989) progressed through the remaining cell cycle, divided and then stopped in G0/G1.
Using aphidicolin, an inhibitor of DNA polymerase a (Huberman, 1981) tumor cell were synchronized at the G1/Sborder. Tumor cell monolayers were incubated with 5 mg/ml aphidicolin for 16 h, detached by trypsinization, released from the block by three washes in fresh medium without FCS and resuspended in complete medium. The synchronized cells were placed into new T75¯asks and harvested after various incubation times (1 ± 24 h) for¯ow cytometry and extraction of total RNA and protein.
Synchronization of cells in the M phase of the cell cycle was accomplished by mitotic`shake-o' of enriched cell monolayers, as described elsewhere (O'Connor and Jackman, 1995) . Enrichment of mitotic cells was achieved by the addition of either colchicine (5 ng/ml, Sigma Chem. Co.) or nocodazole (40 ng/ml, Sigma Chem. Co.) for 16 h to 70% con¯uent cell monolayers.
RNA extraction and quantitative RT ± PCR for IL-2 message in carcinoma cells
Total RNA was extracted from the tumor cells arrested in dierent phases of the cell cycle (G0/G1, S, and G2/M) and from keratinocytes, stimulated T lymphocytes and activated Jurkat cells, using the AGPC method (Chomczynski and Sacchi, 1987) followed by DNaseI (Promega, Madison, WI, USA) treatment.
For reverse transcription, aliquots of the internal standard RNA prepared from pQA-1 plasmid, a gift from Dr David Shire (Sano® Elf Bio Recherches, LabeÁ ge, France), which contains a 262 bp region¯anked by sense IL-2 primer (5'-GTCACAAACAGTGCACCTAC-3') and antisense IL-2 primer (5'-CCCTGGGTCTTAAGTGAAAG-3') (Bouaboula et al., 1992) , were mixed with 300 ng of total cellular RNA and reverse transcribed, using a PCR kit (Perkin-Elmer Corp., Norwalk, CT, USA). Reverse transcription was performed in a volume of 20 ml, containing 5 mM MgC 2 2, 1 mM of each dNTP, 1 U/ml RNase inhibitor, and 2.5 U/ml reverse transcriptase for 15 min at 428C. One half of each RT reaction was then used for PCR, which was performed in a volume of 40 ml by adding MgCl 2 (®nal 2 mM), primers (at a ®nal concentration of 0.4 mM each), 1 mCi [a-32 P]-dCTP (3000 Ci/mmol) and 1 U of Taq polymerase. Thirty-®ve cycles were performed, with denaturing at 948C for 1 min, annealing at 648C for 1 min, and extension at 72oC for 1 min. In each case, one half of the ampli®ed product was electrophoresed on 5% TBE polyacrylamide gel. The gel was dried and exposed to X-ray ®lm with two intensi®er screens for 12 h at 7808C. The amount of the amplicon in each band was detected as c.p.m. of [ 
The enhanced chemiluminescence Western blot assay
Cell lysates (40 or 60 mg protein per lane) were electrophoresed on a sodium dodecyl sulfate (SDS)-polyacrylamide gel and then electrophoretically transferred to a nitrocellulose membrane. The nitrocellulose blot was blocked, washed and incubated with a puri®ed antibody to p27 (13231A, PharMingen), p21 (65951A, PharMingen), Cyclin E (06-137, Oncogene), Cyclin B (sc-752, Santa Cruz) or IL-2 (AB-202-NA, R & D Systems) at a ®nal concentration of 1 mg/ml. After washing, the ®lter was then incubated with a second antibody that was conjugated with horseradish peroxidase. Finally, the ®lter was incubated with the detection reagents and exposed to an X-ray ®lm.
Antisense oligonucleotide treatments
Oligonucleotides (sense and antisense) were selected in the 5' coding region of hIL-2, phosphorothioated and chromatographically puri®ed and used as described by us earlier (Reichert et al, 1999) . Brie¯y, tumor cells maintained in media with reduced serum concentration (1%) were plated at the concentration of 5610 3 cells per well in wells of a 96-well plate and treated with sense (SO) or antisense (ASO) oligonucleotides, mixed with a cationic lipid transfection reagent N-[1-(2,3 Dioleoyloxy) propyl](-N,N,N-trimethyl ammonium methylsulfate (DOTAP, Boehringer Mannheim, Indianapolis, IN, USA) at the ®nal concentration of 5 ml DOTAP/1 mg oligonucleotide for 24 ± 48 h. The cells were then washed and examined for growth inhibition in MTT assays. Cells were also harvested for¯ow cytometry to determine expression of intracytoplasmic IL-2 and for Western blot assays to measure expression of p27 and p21.
In addition, antisense and sense oligonucleotides for p27 5'-GCCGTCTGCTCCACAG-3' and 5'-CTGTGGAGCAGAC-GGC-3' and for p21 5'-GCCGGTTCTGACCTGGCGC-CTCCT-3' and 5'-AGGAGGCGCCATGTAAGAACCG-GC-3' were synthesized, phosphorothioated and mixed with DOTAP and delivered to tumor cells at the ®nal concentration of 0.5 mM. Tumor cells were incubated in the presence of the oligonucleotides/DOTAP mixture for 24 h before harvesting for Western blot or PCR assays.
MTT proliferation assay
Tumor cell lines cultured in the presence of medium, ASO or SO were tested for inhibition of proliferation in MTT assays as previously described (Lin et al., 1995) . Brie¯y, tumor cells (5610 3 cells/well) were seeded in wells of 96-well tissue culture plates containing various concentrations of oligonucleotides in medium at a ®nal volume of 200 ml/well. The plates were incubated in 5% CO 2 in air at 378C for 48 h. Culture medium was then placed with a 200 ml aliqout of MTT solution (0.5 mg/ml). The plates were incubated at 378C for 4 h. Next, MTT solution was replaced with an aliquot (200 ml) of dimethylsulfoxide (DMSO) to dissolve formazan crystals. The plates were placed on a rotator for 15 min, and the optical density (OD) of each well was read in a microplate reader (Dynatech Labs Inc., Chantilly, VA, USA) at the wavelength of 540 nm. The OD readings from at least four wells per each oligonucleotide concentration were used to obtain mean OD 540 +S.D. The % inhibition of proliferation was calculated according to the formula:
where control=OD of cells cultured in medium alone.
Statistical analysis
The signi®cance of observed dierences was calculated using Mann-Whitney U-test, with the aid of the statistical software system SPSS Version 7.0 (SPSS Inc., Chicago, IL, USA).
Abbreviations ASO, antisense oligonucleotide; CDK, cyclin-dependent kinase; Con A, Concanavalin A; HR, human gastric carcinoma; IL-2, Interleukin-2; IL-2R, Interleukin-2 receptor; IP, immunoperoxidase; p27, a CDK inhibitor, also called Kip1; PBL, peripheral blood lymphocytes; PBMC, peripheral blood mononuclear cells; PHA, phytohemagglutinin; PI, propidium iodide; RT ± PCR, reverse-transcription polymerase chain reaction; SCCHN, squamous cell carcinoma of the head and neck.
